Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.54 |
| ▸ | TSHR | P16473 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | ALDH3A1 | P30838 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | HCAR3 | P49019 | 2/20 | 0.36 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5693115 | 0.85 | MAPT (0.40) | MAPTTSHRALDH1A1CYP3A4ALDH3A1 | |
| SCHEMBL3057864 | 0.82 | VCAM1 (0.36) | MAPTTSHRALDH1A1CYP3A4CYP1A2 | |
| SCHEMBL3049772 | 0.82 | AR (0.44) | MAPTTSHRALDH1A1CYP3A4CYP1A2 | |
| SCHEMBL5692137 | 0.82 | MAPT (0.40) | MAPTTSHRALDH1A1CYP3A4CYP1A2 | |
| SCHEMBL3054634 | 0.80 | MAPT (0.63) | MAPTTSHRALDH1A1CYP3A4ALDH3A1 | |
| SCHEMBL3040881 | 0.80 | VCAM1 (0.45) | MAPTTSHRALDH1A1CYP3A4CYP1A2 | |
| SCHEMBL7791752 | 0.76 | MAPT (0.48) | MAPTTSHRALDH1A1L3MBTL1HPGD | |
| SCHEMBL3060140 | 0.74 | MAPT (0.59) | MAPTTSHRALDH1A1CYP3A4L3MBTL1 | |
| SCHEMBL3835000 | 0.73 | MAPT (0.67) | MAPTTSHRALDH1A1CYP3A4L3MBTL1 | |
| SCHEMBL29740665 | 0.73 | MAPT (0.72) | MAPTTSHRALDH1A1CYP3A4L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060148893-A1 | Chemical compounds | SMITHKLINE BEECHAM CORPORATION | 2006-07-06 | — | — | US | claimed |
| EP-1654221-A2 | ANILINE DERIVATIVED ANDROGEN-, GLUCOCORTICOID-, MINERALCORTICOID- AND PROGESTERONE- RECEPTOR MODULATORS | SMITHKLINE BEECHAM CORPORATION (US) | 2006-05-10 | — | — | EP | claimed |
| WO-2005000795-A2 | ANILINE DERIVATIVED ANDROGEN-, GLUCOCORTICOID-, MINERALCORTICOID- AND PROGESTERONE- RECEPTOR MODULATORS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-01-06 | — | — | WO | claimed |
| US-11834458-B2 | Anti-cancer nuclear hormone receptor-targeting compounds | NUVATION BIO INC. (US) | 2023-12-05 | — | — | US | disclosed |
| US-11826430-B2 | Anti-cancer nuclear hormone receptor-targeting compounds | NUVATION BIO INC. (US) | 2023-11-28 | — | — | US | disclosed |
| US-20100222434-A1 | PHARMACEUTICAL COMPOSITION FOR INHIBITING AMYLOID-BETA PROTEIN ACCUMULATION | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2010-09-02 | — | — | US | disclosed |
| EP-2210603-A1 | PHARMACEUTICAL COMPOSITION FOR INHIBITING THE ACCUMULATION OF AMYLOID- B PROTEIN | Sumitomo Chemical Company, Limited (JP) | 2010-07-28 | — | — | EP | disclosed |
| US-20060148893-A1 | Chemical compounds | SMITHKLINE BEECHAM CORPORATION | 2006-07-06 | — | — | US | disclosed |
| EP-1654221-A2 | ANILINE DERIVATIVED ANDROGEN-, GLUCOCORTICOID-, MINERALCORTICOID- AND PROGESTERONE- RECEPTOR MODULATORS | SMITHKLINE BEECHAM CORPORATION (US) | 2006-05-10 | — | — | EP | disclosed |
| WO-2005000795-A2 | ANILINE DERIVATIVED ANDROGEN-, GLUCOCORTICOID-, MINERALCORTICOID- AND PROGESTERONE- RECEPTOR MODULATORS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-01-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100222434-A1 | PHARMACEUTICAL COMPOSITION FOR INHIBITING AMYLOID-BETA PROTEIN ACCUMULATION | APP, PSEN1, BACE1 | MAPT 10/4885TSHR 4649/4885ALDH1A1 3472/4885 |
| US-11834458-B2 | Anti-cancer nuclear hormone receptor-targeting compounds | NCOA1, NCOR1, NCOA3 | MAPT 4011/4885TSHR 115/4885ALDH1A1 3398/4885 |
| US-11826430-B2 | Anti-cancer nuclear hormone receptor-targeting compounds | NCOA1, NCOR1, NCOA3 | MAPT 4011/4885TSHR 115/4885ALDH1A1 3398/4885 |
| US-20060148893-A1 | Chemical compounds | NR3C2, NR5A1, NR3C1 | MAPT 1877/4885TSHR 381/4885ALDH1A1 824/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.